Medicare Part B
‘Bagging’ oncology drugs increases costs for patients
Bagging oncology drugs lowered payments for certain therapies for insurers but increased out-of-pocket costs for patients, according to study results published in JAMA Network Open.
First 10 drugs chosen for Medicare price negotiations
HHS announced the first 10 drugs that will be subject to Medicare price negotiations.
Healio Minute Podcast, Neurology Edition: Top Headlines - Week of June 26, 2023
In this edition, Leqembi shows benefits in early Alzheimer’s, sex before bed has more positive impact on sleep, clearer guidelines needed on melatonin use in children and more.
VIDEO: MedPAC recommendations would balance Medicare budget ‘on the backs of physicians’
Recent recommendations from MedPAC regarding Medicare Part B physician reimbursements will “do nothing to address the root cause” of high drug prices, according to Madelaine A. Feldman, MD, FACR.
HHS announces savings on 43 prescription drugs for Medicare Part B beneficiaries
HHS has released a list of 43 prescription drugs for which Part B beneficiary coinsurances may be lower starting July 1.
CMS announces new Medicare Part B drug inflation rebates
CMS has announced its initial guidance for the new Medicare Prescription Drug Inflation Rebate Program, which it said will reduce drug costs for millions of beneficiaries.
Insulin underuse due to costs remains high in primary care settings
In a recent survey, nearly half of primary care patients with type 1 or type 2 diabetes reported suboptimal insulin use due to costs.
Potential 2022 Medicare Part B increases tied to uncertainty regarding Aduhelm coverage
Additional contingency reserves related to uncertainty surrounding the potential use of Aduhelm by individuals with Medicare contributed to projected increases in the 2022 Medicare Part B premium and deductible, according to CMS.
Top in rheumatology: ‘Most-favored nation’ model, the search for COVID-19 therapies
CMS said it would nix the “most-favored nation” pricing model for Medicare Part B drugs, which was formally introduced in November 2020 and slated to take effect Jan. 1. It was the top story in rheumatology last week.
CMS nixes 'most-favored nation' pricing model for Medicare Part B
CMS plans to rescind a Trump-era interim final rule that would have established a “most-favored nation” pricing model for Medicare Part B drugs, following months of lawsuits that saw the proposal stalled in federal court.